Analysis of the range, economic availability and volume of consumption of antiestrogens for the hormone therapy of ER(+) HER2(−) breast cancer

Authors

  • O. Ya. Mishchenko Institute for Advanced Training of Pharmacy Specialists of the National University of Pharmacy of the Ministry of Health of Ukraine, Kharkiv, Ukraine https://orcid.org/0000-0001-5862-4543
  • Iu. I. Greshko Institute for Advanced Training of Pharmacy Specialists of the National University of Pharmacy of the Ministry of Health of Ukraine, Kharkiv, Ukraine https://orcid.org/0000-0003-3132-4174
  • V. Yu. Adonkina Institute for Advanced Training of Pharmacy Specialists of the National University of Pharmacy of the Ministry of Health of Ukraine, Kharkiv, Ukraine https://orcid.org/0000-0001-5803-1131
  • O. O. Surikov Institute for Advanced Training of Pharmacy Specialists of the National University of Pharmacy of the Ministry of Health of Ukraine, Kharkiv, Ukraine

DOI:

https://doi.org/10.24959/sphhcj.23.306

Keywords:

antiestrogens, affordability, consumption, breast cancer.

Abstract

Aim. To study the range, economic availability and consumption volumes of antiestrogens for the hormone therapy of ER(+) HER2(−) breast cancer.

Materials and methods. The retrospective analysis of the range, as well as the analysis of changes in average retail prices, economic availability and consumption volumes of hormone therapy for ER(+) HER2(−) breast cancer presented at the pharmaceutical market of Ukraine in 2017-2022 were performed.

Results. At the pharmaceutical market of Ukraine in 2017-2022, 3 INNs of anti-estrogens were presented during the entire period under study: tamoxifen (L02B A01), toremifene (L02B A02) and fulvestrant (L02B A03). The value of the solvency adequacy ratio (Ca.s.) of the population for each drug under research decreased at the end of the study period. For almost every trade name (TN) of the drugs studied during individual years, the Ca.s. indicator was slightly higher than in the previous period, but this was not systemic in nature and did not affect the general trend of decreasing Ca.s., which, in turn, indicated an increase in the affordability of all TN of antiestrogens studied for an average citizen of Ukraine. There is an overall clear trend towards a year-on-year decrease in the consumption of anti-estrogens mainly due to a decrease in the consumption of tamoxifen drugs, but there is a steady trend towards an increase in the consumption of fulvestrant.

Conclusions. At the pharmaceutical market of Ukraine within 2017-2022, anti-estrogens for the hormone therapy of ER(+) HER2(–) breast cancer were presented by 3 INNs: tamoxifen, toremifene and fulvestrant. It has been found that for almost all drugs studied there is a steady trend towards increasing economic availability due to an increase in average wages, despite an increase in average retail prices. A trend towards a decrease in the consumption of drugs from the group of anti-estrogens has been determined mainly due to a decrease in the consumption of tamoxifen drugs.

References

Deo, S.V.S., Sharma. J., Kumar, S. (2022). GLOBOCAN 2020 Report on Global Cancer Burden: challenges and opportunities for surgical oncologists. Ann Surg Onco, 29, 6497–6500. doi:10.1245/s10434-022-12151-6.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A. et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71, 3. 209–249.

Konovalenko, V. F., Harashchenko, O. O., Konovalenko, S. V. (2021). Modern approaches to diagnosis and treatment of patients with breast cancer. Oncology, 23, 1–2, 1-9.

Walsh, E. M., Smith, K. L., Stearns, V. (2020). Management of hormone receptor-positive, HER2-negative early breast cancer. Semin Oncol, 47 (4), 187–200.

Dong, Z., Tao, Q., Yan, B., Sun, G. (2020). Availability, prices and affordability of essential medicines in Zhejiang Province, China. PLoS ONE, 15 (11),. e0241761. doi: 10.1371/journal.pone.0241761.

Dong, Z., Zhang, S., Wu, S., Xie, X., Sun, G., Yu, X. (2023). Study on the accessibility and affordability of 50 drugs in Wuhan based on the WHO/HAI standardization method. Frontiers in Public Health, 11, e1108007. doi: 10.3389/fpubh.2023.1108007.

Mishchenko, O. Ya., Greshko, Yu. I., Ostashko, V. F., Bereznyakov, A. V. (2021). Clinical and economic aspects of hormone therapy for ER(+) HER2(−) breast cancer: focus on aromatase inhibitors. Medical case, 3-4, 86-92.

Mnushko, Z. M., Timanyuk, I. V. (2007). The system of ensuring the availability of medicinal products. Bulletin of Pharmacy, 1 (49), 52-57.

Pension Fund of Ukraine. Statistics. Data on the size of the average salary for calculating the pension. Archive. Available at: https://www.pfu.gov.ua/statystyka/pokazniki-serednoyi-zarobitnoyi-plat/arhiv-zapitannya-vidpovidi-peremishhenim-pokazniki-serednoyi-zarobitnoyi-plat/

Tolochko, V. M., Mishchenko, O. Ya., Adonkina, V. Yu. (2015). Beta-adrenoblokatory: doslidzhennia asortymentu, sotsialno-ekonomichnoi dostupnosti ta obsiahiv spozhyvannia v Ukraini. ScienceRise, 12, 4 (17), 20-26.

Morozov, A. M., Yakovleva, L. V., Stepanenko, A. V., Zimenkovskyi, A. B., Parii, V. D., Dumenko, T. M. et al. (2013). Vyvchennia spozhyvannia likarskykh zasobiv za anatomo-terapevtychno-khimichnoiu klasyfikatsiieiu ta vstanovlenymy dobovymy dozamy (ATC/DDD − metodolohiia) : metod, rek. Kyiv: Styl-Yzdat.

ATC/DDD Index 2023. Available at: https://www.whocc.no/atc_ddd_index/?code=L02AB&showdescription=no.

Downloads

Published

2023-11-17

Issue

Vol. 9 No. 4 (2023)

Section

Social marketing and pharmacoeconomic research

License

Copyright (c) 2024 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).